NCT06715007 Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
| NCT ID | NCT06715007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Stroke, Ischemic |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-12-20 |
| Primary Completion | 2025-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-12-20 with a primary completion date of 2025-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).
Eligibility Criteria
Inclusion criteria: 1. Age ≥ 30 years and ≤ 79 years. 2. A recent small subcortical infarct that occurred within 3 weeks prior to randomization; or patient with whiter matter hyperintensities with a 2-3 grading on Fazekas scale. 3. Absence of signs or symptoms of cortical dysfunction, such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect. 4. Modified Rankin score of ≤ 4. 5. In the absence of any other pathology in the parent artery at the site of the origin of the penetrating artery (focal atheroma, parent vessel dissection, vasculitis, vasospasm, and so on). 7\. No ipsilateral cervical carotid stenosis (≥30%) by brain high resolution magnetic resonance imaging (HRMRI) or computed tomography angioplasty (CTA) or (magnetic resonance angioplasty) MRA and cervical artery ultrasound, if qualifying event is hemispheric. No vertebra artery stenosis (≥30%) by brain HRMRI or CTA or MRA and cervical artery ultrasound, if the lesion is in the territory of posterior circulation. 8\. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy. 9\. Patient agrees with follow-up visits and is available by phone. 10. Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed informed consent. Exclusion criteria: 1. Intracranial aneurysms that need surgical treatment. Other significant active neurological illness e.g seizures, multiple sclerosis, intracranial tumor (except meningioma) or any intracranial vascular malformation. 2. Active cardiac disease (atrial fibrillation, myocardial infarct in last six months, active angina, symptomatic cardiac failure). 3. History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural). 4. Known allergy or contraindication to aspirin, clopidogrel, cilostazol, isosorbide mononitrate or statin. 5. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets \< 100,000, hematocrit \< 30, international normalized ratio (INR) \> 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure \> 180 mm Hg or diastolic pressure \> 115 mm Hg), severe liver impairment (aspartate transaminase \[AST\] or alanine transaminase \[ALT\] \> 3 x normal, cirrhosis), creatine kinase \> 5 times the upper limit of normal (ULN) at final screening, severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \< 20mL/min/1.73 square meter at final screening. 6. Major surgery (including open femoral, aortic, cardiac or carotid surgery) within previous 30 days or planned in the 1 year after enrollment. 7. Dementia or psychiatric problem that prevents the patient from relevant evaluation or follow-up reliably. 8. Co-morbid conditions that may limit survival to less than 1 year. 9. Currently breastfeeding, pregnancy, planning to become pregnant and unwilling to use contraception for the duration of this study 10. Unable to tolerate, or contraindication to, MRI. 11. Enrollment in another study that would conflict with the current study.
Contact & Investigator
zhaolu wang, MD
STUDY DIRECTOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06715007 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 79 Years, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06715007 currently recruiting?
Yes, NCT06715007 is actively recruiting participants. Contact the research team at wangzhaolu123@163.com for enrollment information.
Where is the NCT06715007 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06715007 clinical trial?
NCT06715007 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is zhaolu wang, MD at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.